Metraipolis › archive › dc_e39de0ed8a52

Association of Mortality and Aspirin Prescription for COVID-19 Patients at the Veterans Health Administration — Europe PMC PPR:PPR254180

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR254180
DOI
10.1101/2020.12.13.20248147
License (as archived)
CC0-1.0
Archived
2026-11-06T16:46:00.426Z
SHA-256 of the archived text
5dd3406722052ba5dd75d3accea9d684814c545ede4c9ae2f0438701b30d3ab2
Stable URL of this page
https://metraipolis.com/documento/dc_e39de0ed8a52

How to cite

Association of Mortality and Aspirin Prescription for COVID-19 Patients at the Veterans Health Administration — Europe PMC PPR:PPR254180 — Europe PMC, https://europepmc.org/article/PPR/PPR254180 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_e39de0ed8a52 (Metraipolis archive dc_e39de0ed8a52, sha256 5dd3406722052ba5dd75d3accea9d684814c545ede4c9ae2f0438701b30d3ab2)
BibTeX
@misc{dce39de0ed8a52,
  title = {Association of Mortality and Aspirin Prescription for COVID-19 Patients at the Veterans Health Administration — Europe PMC PPR:PPR254180},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR254180},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_e39de0ed8a52; sha256 5dd3406722052ba5dd75d3accea9d684814c545ede4c9ae2f0438701b30d3ab2},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR254180. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

There is growing evidence that thrombotic and inflammatory pathways contribute to the severity of COVID-19. Common medications such as aspirin, that mitigate these pathways, may decrease COVID-19 mortality. This assessment was designed to quantify the correlation between aspirin and mortality for COVID-19 positive patients in our care. Data from the Veterans Health Administration national electronic health record database was utilized for the evaluation. Veterans from across the country with a first positive COVID-19 polymerase chain reaction lab result were included in the evaluation which comprised 28,350 patients from March 2, 2020 to September 13, 2020 for the 14-day mortality cohort and 26,346 patients from March 2, 2020 to August 28, 2020 for the 30-day mortality cohort. Patients were matched via propensity scores and the odds of mortality were then compared. Among COVID-19 positive Veterans, preexisting aspirin prescription was associated with a statistically and clinically significant decrease in overall mortality at 14-days (OR 0.38, 95% CI 0.32-0.46) and at 30-days (OR 0.38, 95% CI 0.33-0.45), cutting the odds of mortality by more than half. Findings demonstrated that pre-diagnosis aspirin prescription was strongly associated with decreased mortality rates for Veterans diagnosed with COVID-19. Prospective evaluation is required to more completely assess this correlation and its implications for patient care.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: medRxiv, 2020 (prima pubblicazione 2020-12-14).
Identificativi: DOI 10.1101/2020.12.13.20248147.
Pagina: https://europepmc.org/article/PPR/PPR254180 — https://doi.org/10.1101/2020.12.13.20248147. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-06T16:42:23.741Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.